Forward Therapeutics Announces Positive Phase 1 Data for Potential Best-in-Class Oral TNFR1 Signaling Inhibitor FT2109, Supporting Advancement into Phase 2 DevelopmentBOSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Forward Therapeutics, Inc. (“Forward” or the “Company”), a clinical-stage biotechnology company developing oral small molecule therapies for inflammation-driven diseases, today announced positive Phase 1 clinical and preclinical data for FT2109, its novel, potential best-in-class oral selective TNFR1 signaling inhibitor. The data are included in two abstracts accepted for presentation at the American College of Rheumatology (ACR) Convergence 2026, taking place November 6–11 in Orlando, Florida.
Forward Therapeutics Announces Completion of Phase 1 Trials with Two Internally Discovered Next-Generation TNF Signaling Inhibitors Supporting Advancement to Phase 2 Clinical DevelopmentPALM BEACH GARDENS, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- Forward Therapeutics, Inc (“Forward” or “the Company”), a clinical-stage biotechnology company developing oral small molecule therapies for inflammation-driven diseases, today announced the successful completion of Phase 1 first-in-human trials for two internally-discovered drug candidates, FT2109 and FT751, and the selection of FT2109 as its lead candidate for advancement into Phase 2 development.
Forward Therapeutics Announces First Participants Dosed in Phase 1 Healthy Volunteer Study of FT2109, a Next-Generation TNF Signaling InhibitorPALM BEACH GARDENS, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Forward Therapeutics, Inc (“Forward”), a biotechnology company developing oral small molecule therapies for inflammation-driven diseases, today announced that the first participants have been dosed in its Phase 1 healthy volunteer trial evaluating FT2109, the company’s second TNF signaling inhibitor in development for chronic inflammatory diseases.
